Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.67 |
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.60 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | GGH | Q92820 | 1/20 | 0.56 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.56 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.54 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698067 | 1.00 | CA2 (0.67) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL715646 | 1.00 | CA2 (0.67) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL28286177 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL28184998 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL28287497 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL28286179 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL28185002 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL4618531 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 | |
| Ammonia Solution, Strong SCHEMBL28375957 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 | |
| SCHEMBL28287499 | 0.98 | CA2 (0.65) | CA2CA1TDP1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117512596-A | Tin-copper-titanium etching solution | 湖北兴福电子材料股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-107442038-B | Ultraviolet response amino acid surfactant and preparation method thereof | 广州天赐高新材料股份有限公司 | 2019-08-09 | — | — | CN | claimed |
| CN-109553619-A | A kind of preparation method of methotrexate (MTX) | 北京斯利安药业有限公司 | 2019-04-02 | — | — | CN | claimed |
| CN-107442038-A | Ultraviolet response amino acid surfactant and preparation method thereof | 广州天赐高新材料股份有限公司 | 2017-12-08 | — | — | CN | claimed |
| US-20170223990-A1 | FOOD PRESERVATION WITH FOLATES | UNIVERSITY OF CALCUTTA (IN) | 2017-08-10 | — | — | US | claimed |
| CN-106432188-A | Preparation method of anti-cancer drug 2-[4-((3S)-3-Piperidinyl) phenyl]-2H-Indazole-7-Formamide | 青岛辰达生物科技有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-106431957-A | Method for synthesizing N-benzoyl glutamic acid being proglumide drug intermediate | 厦门莱恩斯特信息科技有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-106279174-A | A kind of preparation technology of folic acid | 黄冈华阳药业有限公司 | 2017-01-04 | — | — | CN | claimed |
| CN-105481710-A | Synthetic method of proglumide drug intermediate N-benzoyl glutamic acid | CHENGDU DONGDIAN AIER SCIENCE AND TECH CO LTD | 2016-04-13 | — | — | CN | claimed |
| US-8592625-B2 | Process for resolving S-3-(aminomethyl)-5-methylhexanoic acid | Zheinjiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2013-11-26 | — | — | US | claimed |
| US-20070112216-A1 | Method for producing chiral mercapto amino acids | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-05-17 | — | — | US | claimed |
| EP-1457487-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-15 | — | — | EP | claimed |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) | 2004-09-02 | — | — | US | claimed |
| CN-1097459-C | Diazepino-indoles as phosphodiesterase IV inhibitors | JOUVEINAL INST RECH (FR) | 2003-01-01 | — | — | CN | claimed |
| US-6395077-B1 | INKS WITH BENZOYLBENZOIC ACID AND COLORS | XEROX CORPORATION | 2002-05-28 | — | — | US | claimed |
| US-5610316-A | Process for the preparation of (-)-eserethole from mixtures of (-) and (+)-eserethole | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) | 1997-03-11 | — | — | US | claimed |
| EP-0652881-A1 | A PROCESS FOR THE PREPARATION OF (-)-ESERETHOLE FROM MIXTURES OF (-) AND (+)-ESERETHOLE | LABORATORIO CHIMICO INTERNAZIONALE S.p.A. (IT) | 1995-05-17 | — | — | EP | claimed |
| WO-1994003457-A1 | A PROCESS FOR THE PREPARATION OF (-)-ESERETHOLE FROM MIXTURES OF (-) AND (+)-ESERETHOLE | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) | 1994-02-17 | — | — | WO | claimed |
| US-4738811-A | WITH OPTICALLY ACTIVE MONOMER | NIPPON OIL COMPANY, LIMITED (JP) | 1988-04-19 | — | — | US | claimed |
| US-3941776-A | RACEMIZATION OF AMINOLACTAM COMPOUNDS | ALLIED CHEMICAL CORPORATION (US) | 1976-03-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TYR, DDC, TARBP1 | CA2 2307/4885CA1 2106/4885TDP1 1267/4885 |
| US-20070112216-A1 | Method for producing chiral mercapto amino acids | CPN1, AKR1C3, AHCY | CA2 361/4885CA1 113/4885TDP1 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.